Celgene to Buy Juno for $9 Billion, Signaling Cancer Aspirations || CAR-T ||Juno Therapeutics, Inc.

Celgene Corp. agreed to buy Juno Therapeutics Inc. for about $9 billion, one of its largest deals ever, in a bid to expand in the increasingly competitive landscape of cutting-edge cancer treatments.

With Juno, Celgene will gain research into a novel class of therapies known as CAR-T that use the body’s own immune system to fight cancer. The Summit, New Jersey-based company will pay $87 a share in cash, according to a statement Monday. That’s 91 percent above Juno’s closing price Jan. 16, the last trading day before the Wall Street Journal reported the companies were in talks.

Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.

Celgene already owns 9.7 percent in Juno and will offer $87 per share.

Jan 22 (Reuters) - Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.

Celgene already owns 9.7 percent of Juno and will offer $87 per share.

CAR T-cell therapy (CAR is short for chimeric antigen receptor)

If you have any query, feel free to contact me and do not forget to hit the subscribe button.

Thank you.

#ViewsOnline #Cancer #CAR_T